Specialty Genomics Target opportunities in complex generic and specialty pharmaceutical spaces where WES Pharma’s in-house development and end-to-end lifecycle capability can shorten time to market for difficult-to-develop dosage forms, enabling partnerships on development, manufacturing, and co-marketing.

US Market Focus Emphasize U.S. market relevance and FDA-driven development to align with potential buyers seeking regulatory-compliant, locally manufactured generics and specialty products, showcasing WES’s capability to navigate US approvals from R&D to commercial launch.

Scale & Agility Position WES as a nimble, mid-sized partner capable of integrating with larger manufacturers for synergistic development, manufacturing, and marketing while maintaining flexibility and faster decision cycles.

Board & Governance Leverage the addition of an experienced board member to build credibility with potential investors or strategic partners, highlighting governance maturity and access to broader networks for collaborations or funding discussions.

Financial Growth Highlight revenue traction in the $10–$25 million range as an opportunity to discuss scalable manufacturing capacity, co-development deals, and milestone-driven partnerships with larger pharma groups seeking specialized generics and tech-driven formulations.